This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTL Biopharmaceuticals Short Interest DataXTL Biopharmaceuticals (XTLB) has a short interest of 13,300 shares, representing 0.34% of the float (the number of shares available for trading by the public). This marks a -47.01% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 10,548 shares to cover all short positions.Current Short Interest13,300 sharesPrevious Short Interest25,100 sharesChange Vs. Previous Month-47.01%Dollar Volume Sold Short$17.96 thousandShort Interest Ratio0.4 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares5,450,000 sharesShort Percent of Float0.34%Today's Trading Volume0 sharesAverage Trading Volume10,548 sharesToday's Volume Vs. Average0% Short Selling XTL Biopharmaceuticals? Sign up to receive the latest short interest report for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartXTLB Short Interest Over TimeXTLB Days to Cover Over TimeXTLB Percentage of Float Shorted Over Time XTL Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202513,300 shares $17.96 thousand -47.0%0.3%0.4 $1.35 7/15/202525,100 shares $39.91 thousand +796.4%N/A0.7 $1.59 6/30/20252,800 shares $3.16 thousand -92.8%0.1%0.2 $1.13 6/15/202538,900 shares $49.79 thousand +6.3%1.0%1.4 $1.28 5/31/202536,600 shares $43.92 thousand -4.7%0.9%4.6 $1.20 5/15/202538,400 shares $43.01 thousand -20.0%1.0%4.5 $1.12 4/30/202548,000 shares $68.16 thousand -11.3%N/A6.1 $1.42 4/15/202554,100 shares $63.30 thousand -1.1%1.4%10.4 $1.17 3/31/202554,700 shares $65.91 thousand -2.8%1.4%9.4 $1.21 3/15/202556,300 shares $69.25 thousand -17.3%1.5%6.7 $1.23 Get the Latest News and Ratings for XTLB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/202568,100 shares $92.28 thousand -16.0%1.8%6.5 $1.36 2/15/202581,100 shares $133.09 thousand -4.1%2.1%8.1 $1.64 1/31/202584,600 shares $138.32 thousand -7.1%N/A7.8 $1.64 1/15/202591,100 shares $169.45 thousand -1.1%N/A2.1 $1.86 12/31/202492,100 shares $171.31 thousand +30.1%N/A2.1 $1.86 12/15/202470,800 shares $127.44 thousand -5.6%N/A1.7 $1.80 11/30/202475,000 shares $141 thousand -0.3%N/A1.9 $1.88 11/15/202475,200 shares $138.37 thousand -64.8%N/A1.9 $1.84 10/31/2024213,400 shares $475.88 thousand +2,381.4%N/A5.4 $2.23 10/15/20248,600 shares $19.09 thousand -41.5%N/A1 $2.22 9/30/202414,700 shares $35.57 thousand +51.6%N/A1.4 $2.42 9/15/20249,700 shares $25.50 thousand +1.0%N/A0.9 $2.63 8/31/20249,600 shares $26.78 thousand -7.7%N/A0.6 $2.79 8/15/202410,400 shares $29.02 thousand +103.9%N/A0.6 $2.79 7/31/20245,100 shares $14.69 thousand -64.3%N/A0.3 $2.88 7/15/202414,300 shares $35.61 thousand -19.2%N/A0.8 $2.49 6/30/202417,700 shares $43.01 thousand +78.8%N/A0.8 $2.43 6/15/20249,900 shares $20.20 thousand -55.0%N/A0 $2.04 5/31/202422,000 shares $57.20 thousand -13.4%N/A0 $2.60 5/15/202425,400 shares $69.60 thousand +13.4%N/A0 $2.74 4/30/202422,400 shares $57.79 thousand -62.8%N/A0 $2.58 4/15/202460,200 shares $161.34 thousand -86.2%N/A0.1 $2.68 3/31/2024437,200 shares $1.23 million +21,760.0%N/A0.6 $2.81 3/15/20242,000 shares $1.76 thousand +11.1%N/A0 $0.88 2/29/20241,800 shares $1.53 thousand -37.9%N/A0.6 $0.85 2/15/20242,900 shares $2.61 thousand -42.0%N/A0.9 $0.90 1/31/20245,000 shares $4.38 thousand -27.5%N/A1.4 $0.88 1/15/20246,900 shares $6.01 thousand +1.5%N/A1.9 $0.87 12/31/20236,800 shares $6.87 thousand -32.7%N/A1.7 $1.01 12/15/202310,100 shares $9.97 thousand -15.8%N/A3.9 $0.99Elon Musk’s New Technology (Ad)Elon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.Get the full details on the AI company behind Musk’s next big move. 11/30/202312,000 shares $12.36 thousand +36.4%N/A5.7 $1.03 11/15/20238,800 shares $6.86 thousand -24.8%N/A2.7 $0.78 10/31/202311,700 shares $10.15 thousand +62.5%N/A3.2 $0.87 10/15/20237,200 shares $6.48 thousand -22.6%N/A1.3 $0.90 9/30/20239,300 shares $8.35 thousand -3.1%N/A1.7 $0.90 9/15/20239,600 shares $9.31 thousand +29.7%N/A1.5 $0.97 8/31/20237,400 shares $7.77 thousand +236.4%N/A0.5 $1.05 8/15/20232,200 shares $2.09 thousand +29.4%N/A0.2 $0.95 7/31/20231,700 shares $1.39 thousand -19.1%N/A0.1 $0.82 7/15/20232,100 shares $2.14 thousand -16.0%N/A0.1 $1.02 6/30/20232,500 shares $2.38 thousand -28.6%N/A0.2 $0.95 6/15/20233,500 shares $4.62 thousand -25.5%N/A0.2 $1.32 5/31/20234,700 shares $5.73 thousand +27.0%N/A0.6 $1.22 5/15/20233,700 shares $4.48 thousand +23.3%N/A0.5 $1.21 4/30/20233,000 shares $3.36 thousand -55.2%N/A0.5 $1.12 4/15/20236,700 shares $8.24 thousand -23.0%N/A1.7 $1.23 3/31/20238,700 shares $11.05 thousand +117.5%N/A4.1 $1.27 3/15/20234,000 shares $4.92 thousand +2.6%N/A1.6 $1.23 2/28/20233,900 shares $5.46 thousand -7.1%N/A1.3 $1.40 2/15/20234,200 shares $5.59 thousand -16.0%N/A1.5 $1.33 1/31/20235,000 shares $5.85 thousand -12.3%N/A1.4 $1.17 1/15/20235,700 shares $7.87 thousand +2,750.0%N/A1.7 $1.38 12/30/2022200 shares $242.00 -95.7%N/A0.1 $1.21 12/15/20224,700 shares $5.69 thousand -6.0%N/A1 $1.21 11/30/20225,000 shares $6.65 thousand +6.4%N/A1.2 $1.33 11/15/20224,700 shares $6.67 thousand +261.5%N/A1 $1.42 10/31/20221,300 shares $1.68 thousand -40.9%N/A0.3 $1.29 10/15/20222,200 shares $2.65 thousand +83.3%N/A0.3 $1.21 9/30/20221,200 shares $1.33 thousand -77.4%N/A0.2 $1.11 9/15/20225,300 shares $7.16 thousand -22.1%N/A0.9 $1.35 8/31/20226,800 shares $10.06 thousand +4.6%N/A1.2 $1.48 8/15/20226,500 shares $11.12 thousand +8.3%N/A1.2 $1.71 7/31/20226,000 shares $9.78 thousand -25.9%N/A1.1 $1.63 7/15/20228,100 shares $12.23 thousand +42.1%N/A2.9 $1.51 6/30/20225,700 shares $8.66 thousand +11.8%N/A1.7 $1.52 6/15/20225,100 shares $7.85 thousand -13.6%N/A1.5 $1.54 5/31/20225,900 shares $10.71 thousand -37.2%N/A0.9 $1.82 5/15/20229,400 shares $15.89 thousand +20.5%N/A1.5 $1.69 4/30/20227,800 shares $17.16 thousand +9.9%N/A1.4 $2.20 4/15/20227,100 shares $16.69 thousand +16.4%N/A1.2 $2.35 3/31/20226,100 shares $14.46 thousand +96.8%N/A0.9 $2.37 3/15/20223,100 shares $6.62 thousand +121.4%N/A0.3 $2.13 2/28/20221,400 shares $3.33 thousand -17.7%N/A0.1 $2.38 2/15/20221,700 shares $4.11 thousand No ChangeN/A0.1 $2.42 1/31/20221,700 shares $4.28 thousand -56.4%N/A0.1 $2.52 1/15/20223,900 shares $11.35 thousand -17.0%N/A0.1 $2.91 12/31/20214,700 shares $13.02 thousand +147.4%N/A0.2 $2.77 12/15/20211,900 shares $5.57 thousand -64.2%N/A0.1 $2.93 11/30/20215,300 shares $16.96 thousand +960.0%N/A0.2 $3.20 11/15/2021500 shares $1.79 thousand -58.3%N/A0 $3.58Elon Musk’s New Technology (Ad)Elon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.Get the full details on the AI company behind Musk’s next big move. 10/29/20211,200 shares $4.58 thousand -60.0%N/A0 $3.82 10/15/20213,000 shares $11.79 thousand -85.2%N/A0 $3.93 9/30/202120,200 shares $88.48 thousand +1.0%N/A0.1 $4.38 9/15/202120,000 shares $82.80 thousand -68.7%N/A0.1 $4.14 8/31/202163,900 shares $316.31 thousand +75.6%N/A0.4 $4.95 8/13/202136,400 shares $129.22 thousand -15.7%N/A0.3 $3.55 7/30/202143,200 shares $151.20 thousand +37.6%N/A0.5 $3.50 7/15/202131,400 shares $108.96 thousand -35.3%N/A0.4 $3.47 6/30/202148,500 shares $193.52 thousand +40.2%N/A3.4 $3.99 6/15/202134,600 shares $119.37 thousand -2.8%N/A2.1 $3.45 5/28/202135,600 shares $125.68 thousand +14.8%N/A1.5 $3.53 5/14/202131,000 shares $103.23 thousand -19.7%N/A0.1 $3.33 4/30/202138,600 shares $137.42 thousand -5.6%N/A0.1 $3.56 4/15/202140,900 shares $132.52 thousand -1.2%N/A0.2 $3.24 3/31/202141,400 shares $136.21 thousand -19.8%N/A0.2 $3.29 3/15/202151,600 shares $174.92 thousand +719.1%N/A0.2 $3.39 2/26/20216,300 shares $19.15 thousand -77.7%N/A0 $3.04 2/12/202128,200 shares $106.60 thousand +464.0%N/A1 $3.78 1/29/20215,000 shares $16.10 thousand -76.5%N/A0.2 $3.22 1/15/202121,300 shares $84.14 thousand +88.5%N/A0.8 $3.95 12/31/202011,300 shares $35.76 thousand -76.6%N/A0.4 $3.17 12/15/202048,200 shares $126.77 thousand +518.0%N/A2.5 $2.63 11/30/20207,800 shares $19.57 thousand -34.5%N/A0.5 $2.51 10/30/20206,900 shares $15.32 thousand -46.1%N/A0.4 $2.22 10/15/202012,800 shares $27.90 thousand -14.1%N/A0.7 $2.18 9/30/202014,900 shares $28.31 thousand +156.9%N/A0.9 $1.90 9/15/20205,800 shares $12.59 thousand +65.7%N/A0.3 $2.17 8/31/20203,500 shares $5.95 thousand +483.3%N/A0.1 $1.70 XTLB Short Interest - Frequently Asked Questions What is XTL Biopharmaceuticals' current short interest? Short interest is the volume of XTL Biopharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 13,300 shares of XTLB short. 0.34% of XTL Biopharmaceuticals' shares are currently sold short. Learn More on XTL Biopharmaceuticals' current short interest. What is a good short interest percentage for XTL Biopharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.34% of XTL Biopharmaceuticals' floating shares are currently sold short. Is XTL Biopharmaceuticals' short interest increasing or decreasing? XTL Biopharmaceuticals saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 13,300 shares, a drop of 47.0% from the previous total of 25,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does XTL Biopharmaceuticals' short interest compare to its competitors? 0.34% of XTL Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to XTL Biopharmaceuticals: BioXcel Therapeutics, Inc. (4.84%), Dyadic International Inc. (0.37%), Kezar Life Sciences, Inc. (9.46%), Cadrenal Therapeutics, Inc. (2.39%), MIRA Pharmaceuticals, Inc. (3.01%), Tenax Therapeutics, Inc. (9.22%), CASI Pharmaceuticals Inc. (0.93%), Envoy Medical, Inc. (0.90%), Vivos Therapeutics, Inc. (7.89%), Cosmos Health Inc. (3.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short XTL Biopharmaceuticals stock? Short selling XTLB is an investing strategy that aims to generate trading profit from XTL Biopharmaceuticals as its price is falling. XTLB shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against XTL Biopharmaceuticals? A short squeeze for XTL Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XTLB, which in turn drives the price of the stock up even further. How often is XTL Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XTLB, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies BioXcel Therapeutics Short Squeeze Dyadic International Short Squeeze Kezar Life Sciences Short Squeeze Cadrenal Therapeutics Short Squeeze MIRA Pharmaceuticals Short Squeeze Tenax Therapeutics Short Squeeze CASI Pharmaceuticals Short Squeeze Envoy Medical Short Squeeze Vivos Therapeutics Short Squeeze Cosmos Health Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XTLB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access